• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Sobi to refile Gamifant following CHMP rejection pharmatimes
    July 28, 2020
    Sobi has announced its intent to file for a re-examination of Gamifant (emapalumab) in Europe following negative opinion by the European Medicines Agency's human medicines committee.
  • Sobi snags FDA nod for rare disease drug Gamifant fiercepharma
    November 22, 2018
    Several months after scooping up global rights to emapalumab in a $452 million deal, Sobi has won approval for the drug to treat certain patients with primary hemophagocytic lymphohistiocytosis.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service